CLBT vs IIIV

For growth investors, Cellebrite DI Ltd.

(CLBT) is the stronger pick with 18. 6% revenue growth year-over-year, versus -7. 3% for i3 Verticals, Inc. (IIIV). i3 Verticals, Inc. (IIIV) offers the better valuation at 40. 9x trailing P/E (20. 3x forward), making it the more compelling value choice. Analysts rate Cellebrite DI Ltd. (CLBT) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, i3 Verticals, Inc.

(IIIV) is the cheapest at 40. 9x versus Cellebrite DI Ltd. at 44. 5x. On forward P/E, i3 Verticals, Inc. is actually cheaper at 20. 3x.

Over the past 5 years, Cellebrite DI Ltd.

(CLBT) delivered a total return of +39. 9%, compared to -27. 6% for i3 Verticals, Inc. (IIIV). Over 10 years, the gap is even starker: CLBT returned +43. 0% versus IIIV's +24. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cellebrite DI Ltd.

(CLBT) is the lower-risk stock at 0. 76β versus i3 Verticals, Inc. 's 0. 92β — meaning IIIV is approximately 20% more volatile than CLBT relative to the S&P 500. On balance sheet safety, i3 Verticals, Inc. (IIIV) carries a lower debt/equity ratio of 1% versus 5% for Cellebrite DI Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cellebrite DI Ltd.

(CLBT) is pulling ahead at 18. 6% versus -7. 3% for i3 Verticals, Inc. (IIIV). On earnings-per-share growth, the picture is similar: Cellebrite DI Ltd. grew EPS 123. 0% year-over-year, compared to -87. 9% for i3 Verticals, Inc.. Over a 3-year CAGR, CLBT leads at 20. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cellebrite DI Ltd.

(CLBT) is the more profitable company, earning 16. 5% net margin versus 8. 4% for i3 Verticals, Inc. — meaning it keeps 16. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CLBT leads at 14. 0% versus 1. 9% for IIIV. At the gross margin level — before operating expenses — CLBT leads at 84. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, i3 Verticals, Inc.

(IIIV) trades at 20. 3x forward P/E versus 37. 5x for Cellebrite DI Ltd. — 17. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLBT: 49. 7% to $20. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cellebrite DI Ltd.

(CLBT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 76)). Both have compounded well over 10 years (CLBT: +43. 0%, IIIV: +24. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CLBT is a small-cap high-growth stock; IIIV is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.